The company identifies new therapies, specifically GLP-1 agonists and SGLT2 inhibitors, as a factor that could reduce long-term demand for dialysis treatments. This potential disruption to the total addressable market creates a strategic need to diversify services and invest in new care models.
Filing excerpt
...other reductions in demand for dialysis treatments over time, including for example, as a result of the introduction of certain innovative technologies, drugs, treatments or therapies, such as the glucagon-like peptide 1 (GLP-1) receptor agonist or SGLT2 inhibitors.
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
Regions named
sec-10kmarketShareLossGet every 10-K signal for DaVita and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at DaVita this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/9b5cbb94-0c9a-4234-9824-b8ba341aa844 returns this record as JSON. POST /v1/companies/enrich returns every signal for davita.com.
{
"signal_id": "9b5cbb94-0c9a-4234-9824-b8ba341aa844",
"signal_type": "sec-10k",
"signal_subtype": "marketShareLoss",
"detected_at": "2026-02-17T06:37:53.052+00:00",
"company": {
"name": "DaVita",
"domain": "davita.com"
},
"data": {
"detail": "The company identifies new therapies, specifically GLP-1 agonists and SGLT2 inhibitors, as a factor that could reduce long-term demand for dialysis treatments. This potential disruption to the total addressable market creates a strategic need to diversify services and invest in new care models.",
"metrics": {
"timeframe": "multi_year"
},
"summary": "New drug classes like GLP-1s and SGLT2s pose a threat to future dialysis patient volume.",
"excerpts": "...other reductions in demand for dialysis treatments over time, including for example, as a result of the introduction of certain innovative technologies, drugs, treatments or therapies, such as the glucagon-like peptide 1 (GLP-1) receptor agonist or SGLT2 inhibitors.",
"relevance": 0.8,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/927066/000092706626000012/dva-20251231.htm",
"filing_date": "2026-02-11",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Urgency to improve",
"signal_category": "market",
"regions_mentioned": [
"U.S."
],
"technologies_mentioned": [
"GLP-1",
"SGLT2 inhibitors"
]
}
}
curl https://signals.autobound.ai/v1/signals/9b5cbb94-0c9a-4234-9824-b8ba341aa844 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"davita.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.